Overview

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour. The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborator:
National Medical Research Council (NMRC), Singapore
Treatments:
Bexarotene
Capecitabine